<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - QUETIAPINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>QUETIAPINE</h1>

        <p><a href="../drugClass/PHP34569.html">ANTIPSYCHOTIC DRUGS</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Schizophrenia</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                25 mg twice daily for day 1, then 50 mg twice daily for day 2, then 100 mg twice daily for day 3, then 150 mg twice daily for day 4, then, adjusted according to response, usual dose 300&#8211;450 mg daily in 2 divided doses, the rate of dose titration may need to be slower and the daily dose lower in elderly patients; maximum 750 mg per day.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                300 mg once daily for day 1, then 600 mg once daily for day 2, then, adjusted according to response, usual dose 600 mg once daily, maximum dose under specialist supervision; maximum 800 mg per day.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Initially 50 mg once daily, adjusted according to response. adjusted in steps of 50 mg daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of mania in bipolar disorder</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                50 mg twice daily for day 1, then 100 mg twice daily for day 2, then 150 mg twice daily for day 3, then 200 mg twice daily for day 4, then adjusted in steps of up to 200 mg daily, adjusted according to response, usual dose 400&#8211;800 mg daily in 2 divided doses, the rate of dose titration may need to be slower and the daily dose lower in elderly patients; maximum 800 mg per day.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                300 mg once daily for day 1, then 600 mg once daily for day 2, then, adjusted according to response, usual dose 400&#8211;800 mg once daily.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Initially 50 mg once daily, adjusted according to response. adjusted in steps of 50 mg daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of depression in bipolar disorder</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                50 mg once daily for day 1, dose to be taken at bedtime, then 100 mg once daily for day 2, then 200 mg once daily for day 3, then 300 mg once daily for day 4, then, adjusted according to response; usual dose 300 mg once daily, the rate of dose titration may need to be slower and the daily dose lower in elderly patients; maximum 600 mg per day.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                50 mg once daily for day 1, dose to be taken at bedtime, then 100 mg once daily for day 2, then 200 mg once daily for day 3, then 300 mg once daily for day 4, then, adjusted according to response; usual dose 300 mg once daily; maximum 600 mg per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of mania and depression in bipolar disorder</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Continue at the dose effective for treatment of bipolar disorder and adjust to lowest effective dose; usual dose 300&#8211;800 mg daily in 2 divided doses.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Continue at the dose effective for treatment of bipolar disorder and adjust to lowest effective dose; usual dose 300&#8211;800 mg once daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Adjunctive treatment of major depression</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                50 mg once daily for 2 days, dose to be taken at bedtime, then 150 mg once daily for 2 days, then, adjusted according to response, usual dose 150&#8211;300 mg once daily.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Initially 50 mg once daily for 3 days, then increased if necessary to 100 mg once daily for 4 days, then adjusted in steps of 50 mg, adjusted according to response, usual dose 50&#8211;300 mg once daily, dose of 300 mg should not be reached before day 22 of treatment.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>Patients can be switched from immediate-release to modified-release tablets at the equivalent daily dose; to maintain clinical response, dose titration may be required.</p>
            </section>
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>
            <b>Quetiapine</b> is a dopamine D<sub>1</sub>, dopamine D<sub>2</sub>, 5-HT<sub>2</sub>, alpha<sub>1</sub>-adrenoceptor, and histamine-1 receptor antagonist.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Use only if potential benefit outweighs risk.</p><p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>For <i>immediate-release tablets</i>, initially 25&#8239;mg daily, increased daily in steps of 25&#8211;50&#8239;mg.</p><p>For <i>modified-release tablets</i>, initially 50&#8239;mg daily, increased daily in steps of 50&#8239;mg.</p>
            </section>
      </section>



      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Asthenia, dysarthria, dyspnoea, elevated plasma-cholesterol concentrations, elevated plasma-triglyceride concentrations, increased appetite, irritability, peripheral oedema, sleep disorders,
              </p>
              <p>
                <strong>uncommon:</strong> Hyponatraemia, hypothyroidism, restless legs syndrome, rhinitis,
              </p>
              <p>
                <strong>rare:</strong> Hepatitis, pancreatitis,
              </p>
              <p>
                <strong>veryRare:</strong> Angioedema, inappropriate secretion of antidiuretic hormone, rhabdomyolysis, Stevens-Johnson syndrome,
              </p>
              <p>
                <strong>notKnown:</strong> Suicidal behaviour (particularly on initiation), toxic epidermal necrolysis,
              </p>
        
        
        
      </section>





      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Cerebrovascular disease
          </li>
          <li>
            elderly
          </li>
          <li>
            patients at risk of aspiration pneumonia
          </li>
          <li>
            treatment of depression in patients under 25 years (increased risk of suicide)
          </li>
        </ul>
      </section>













      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of QUETIAPINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            oral solution,
            powder,

            <div id="PHP77912"><a href="../medicinalForm/PHP77912.html" data-target="#PHP77912" data-action="load">Tablet</a></div>
            <div id="PHP77924"><a href="../medicinalForm/PHP77924.html" data-target="#PHP77924" data-action="load">Modified-release tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
